Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Publication of CR6952ApublicationCriticalpatent/CR6952A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Esta invencion se refiere a agonistas de prostaglandinas selectivos para el receptor EP4 de Formula I. Tambien se refiere a composiciones farmaceuticas que contienen esos compuestos. Tambien se refiere a procedimientos de tratamiento de afecciones que presentan una baja masa osea particularmente osteoporosis, fragilidad, una fractura o defecto oseo, perdida de hueso idiopatica infantil, perdida de hueso albeolar, perdida de hueso mandibular, osteotomia, perdida de hueso asociada con periodontitis o encarnamiento protesico en un mamifero, que comprende en administrar esos compuestos.This invention relates to prostaglandin agonists selective for the EP4 receptor of Formula I. It also refers to pharmaceutical compositions containing those compounds. It also refers to procedures for treating conditions that have low bone mass, particularly osteoporosis, fragility, a fracture or bone defect, loss of childhood idiopathic bone, loss of albeolar bone, loss of mandibular bone, osteotomy, bone loss associated with periodontitis or prosthetic incarnation in a mammal, which includes administering those compounds.
CR6952A2000-11-272003-04-07
SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS
CR6952A
(en)
Compound, pharmaceutical composition, process for preparing a pharmaceutical composition, methods for inhibiting cathepsin activity in a mammal in need thereof, for treating or preventing a disease, for treating cathepsin-dependent conditions in a mammal in need thereof, for inhibiting bone resorption, to increase bone mineral density, and to reduce the risk of fractures